menu
    • menu
    [{"orgOrder":0,"company":"Belief BioMed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Dalnacogene Ponparvovec","moa":"FIX gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Belief BioMed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Belief BioMed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Shanghai Mianyi Biopharmaceutical Co., Ltd. | Shanghai Xinzhi BioMed Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BBM-D101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Belief BioMed \/ Shanghai Mianyi Biopharmaceutical Co., Ltd. | Shanghai Xinzhi BioMed Co., Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Belief BioMed \/ Shanghai Mianyi Biopharmaceutical Co., Ltd. | Shanghai Xinzhi BioMed Co., Ltd"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Shanghai MYGT Biopharmaceutical LLC","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BBM-H803","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Belief BioMed \/ Shanghai MYGT Biopharmaceutical LLC","highestDevelopmentStatusID":"7","companyTruncated":"Belief BioMed \/ Shanghai MYGT Biopharmaceutical LLC"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BBM-H803","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Belief BioMed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Belief BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BBM-H901","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Belief BioMed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belief BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BBM-H901","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Belief BioMed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belief BioMed \/ Undisclosed"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"AskBio","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Belief BioMed \/ AskBio","highestDevelopmentStatusID":"3","companyTruncated":"Belief BioMed \/ AskBio"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BBM-A101","moa":"IL-1RA","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Belief BioMed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Belief BioMed \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Belief BioMed

    Menu

    Belief BioMed

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBM-A101

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-A101 in the Treatment of Knee Osteoa...

                            Details : BBM-A101 is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 30, 2025

                            Lead Product(s) : BBM-A101

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBM-D101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Shanghai Mianyi Biopharmaceutical Co., Ltd. | Shanghai Xinzhi BioMed Co., Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of BBM-D101 Safety and Efficacy In Duchenne Muscular Dystrophy

                            Details : BBM-D101 is a drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Muscular Dystrophy, Duchenne.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 10, 2025

                            Lead Product(s) : BBM-D101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Shanghai Mianyi Biopharmaceutical Co., Ltd. | Shanghai Xinzhi BioMed Co., Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalnacogene Ponparvovec

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Belief BioMed and Takeda Launch China’s First Hemophilia B Gene Therapy

                            Details : BBM-H901 (dalnacogene ponparvovec) based on a recombinant adeno-associated virus (rAAV) vector, can deliver the optimized human coagulation FIX gene into liver cells of patients with hemophilia B.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 10, 2025

                            Lead Product(s) : Dalnacogene Ponparvovec

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : AskBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Belief BioMed to Collaborate with AskBio to Explore the Potential of New Gene Therapies

                            Details : Through the collaboration, the companies will combine efforts & experience in gene therapy technology to explore potential therapies in diseases that may be treatable using a liver-targeted approach.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 25, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : AskBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBM-H803

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Belief BioMed Completes Dosing of First Subject in Registrational Trial for Hemophilia A

                            Details : BBM-H803 is an AAV-based gene therapy. It is administered intravenously to deliver the coagulation factor Ⅷ gene into the body of patients with hemophilia A,

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 03, 2024

                            Lead Product(s) : BBM-H803

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBM-H803

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Shanghai MYGT Biopharmaceutical LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs

                            Details : BBM-H803 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hemophilia A.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 01, 2023

                            Lead Product(s) : BBM-H803

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Shanghai MYGT Biopharmaceutical LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBM-H901

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Belief BioMed Announces a Key Milestone of Dosing Completion for All Subjects in its Registrational Clinical T...

                            Details : BBM-H901 is an adeno-associated virus (AAV) gene therapy, which is given to introduce the human factor Ⅸ (FⅨ) gene into the body of hemophilia B patient, thus maintaining the levels of coagulation factors.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 23, 2023

                            Lead Product(s) : BBM-H901

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Belief BioMed

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBM-H901

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug

                            Details : BBM-H901 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hemophilia B.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 24, 2022

                            Lead Product(s) : BBM-H901

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth